The US Food and Drug Administration (FDA) has approved Boston Scientific’s expanded instructions for use (IFU) labelling of the Farapulse pulsed field ablation (PFA) system. The approval marks a ...

Boston Scientific has received Food and Drug Administration approval for a new pulsed field ablation catheter that is indicated for use as an adjunctive device in a type of ablation that is performed ...

Pulsed-Field Ablation, one of the hottest and most competitive segments in medtech, was a major topic of discussion during Boston Scientific’s presentation at the J.P. Morgan Healthcare Conference ...

Boston Scientific Corporation (NYSE:BSX) is one of Goldman Sachs’ top healthcare stock picks. On July 7, Boston Scientific (NYSE:BSX) saw its shares rise as TD Cowen reaffirmed its Buy rating and $115 ...

Boston Scientific is proving itself to be a pivotal force in the pulsed-field ablation space. The Marlborough, MA-based company continues to be at the forefront of PFA with its technology The firm ...

Boston Scientific has proved to be a fierce competitor among the three major cardiac device makers, with a record of meaningful innovation and impressive operational chops. Even a prolonged period of ...

Boston Scientific reported fourth-quarter results that featured operational revenue and adjusted earnings per share growth of 14% year over year, along with management expectations for midteens growth ...

Atrial fibrillation (AF or AFib) is one of the most common abnormal heart rhythms, affecting nearly 38 million people worldwide — a figure projected to nearly triple by 2030. Boston Scientific BSX ...